Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC

Inclusion Criteria: * Histologically confirmed rectal adenocarcinoma, classified as stage II (T3-4N0) or stage III (T1-4N1-2) by MRI and CT; * Middle and low rectal cancer with the lower pole of the tumor less than 12 cm from the anal margin; * The multidisciplinary cancer committee recommended neoadjuvant radiotherapy, chemotherapy and surgery; * ECOG PS 0-1; * Expected survival ≥ 2 years; * Have not received any anti-tumor treatment; * Have at least one measurable lesion; * Sufficient organs and bone marrow functions; * Women of childbearing age need to take effective contraceptive measures; Exclusion Criteria: * Patients with surgical contraindication; * Patients with familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), active Crohn's disease or active ulcerative colitis; * Other malignant tumors found within 5 years before enrollment, except skin basal cell or squamous cell carcinoma, or cervical carcinoma in situ after radical surgery; * Serious cardiovascular disease, including unstable angina pectoris or myocardial infarction, occurred within 6 months before enrollment; * International normalized ratio (INR)\>1.5 or partially activated prothrombin time (APTT)\>1.5 × ULN； * Investigators judged clinically significant electrolyte abnormalities; * Hypertension that could not be controlled by drugs before enrollment, which was defined as: systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg; * Poorly controlled diabetes mellitus before enrollment (fasting glucose concentration ≥ CTCAE level 2 after regular treatment); * Active ulcer of stomach and duodenum, ulcerative colitis and other digestive tract diseases before enrollment, or other conditions that may cause gastrointestinal bleeding and perforation judged by the researcher; * Serious active bleeding, hemoptysis (\>5 mL fresh blood within 4 weeks) or thromboembolism (including stroke and/or transient ischemic attack) occurred within 12 months before enrollment; * Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure New York Heart Association (NYHA) grade\>2; Ventricular arrhythmias requiring medication; LVEF\<50%; * Active or uncontrollable serious infection (≥ CTCAE v5.0 grade 2 infection); * Known human immunodeficiency virus (HIV) infection. A known history of liver disease with clinical significance, including viral hepatitis \[People who are known to be carriers of hepatitis B virus (HBV) must exclude active HBV infection, that is, HBV DNA positive (\>1 × 104 copies/mL or\>2000 IU/ml); Known hepatitis C virus infection (HCV) and HCV RNA positive (\>1 × 103 copies/mL); * Unrelieved toxic reaction caused by any previous anti-cancer treatment higher than CTCAE v5.0 grade 1 or above; * Routine urine test showed that urinary protein ≥ 2+, and 24-hour urinary protein volume\>1.0g.